Board Meeting on 30 Oct 2026 to consider Q2 and H1 FY27 results

EBITDA margin compressionExceptional itemResults View source PDF Explain this filing

SUNPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.0%Reaction day

₹1746.40

prior close

₹1736.00

announcement price

After-mkt

timing

Nifty 100market+1.3%-0.2% vs market

Pharmaceuticals peers, median of 172sector-0.6%+1.7% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty 100 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+0.3

15m

+0.5

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.0+1.3-0.2-0.6+1.7

Next day

+0.7+1.9-1.2-0.7+1.4

-0.2+0.9-1.1-1.9+1.7

-0.1+0.3-0.4-3.5+3.5

+0.7-0.2+0.9-4.4+5.1

+0.1-0.9+1.0-6.1+6.2

+0.3+0.0+0.3-2.9+3.1

15d

+6.5pendingpending-1.1+7.6

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sun Pharma has informed stock exchanges that its Board of Directors will meet on Friday, 30 October 2026 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30 September 2026. The trading window for dealing in company securities is already closed from 1 October 2026 and will remain closed until 48 hours after results are declared, up to 1 November 2026.

Likely market impact

Routine pre-results intimation. No new financial information. Investors should await the Q2 FY27 results announcement on or after 30 October 2026.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹16,199 Cr	₹14,478 Cr	+11.9%
Operating profit	₹3,911 Cr	₹3,698 Cr	+5.8%
Profit after tax	₹1,995 Cr	₹3,125 Cr	−36.2%
EBITDA margin	21.4%	31.3%	−9.8 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.